News
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
Melbourne biotech Paradigm Biopharmaceuticals appointed FTI Consulting administrators after its Phase 3 trial failed an interim efficacy threshold, and now seeks to restructure debts via a deed of company arrangement.